Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 151

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 151
---
 infrastructure build-out, and validation support; |

| • |     | expenses incurred under agreements with consultants engaged in research and development functions; and |

| • |     | expenses related to regulatory affairs. |

We expense research and development costs in the periods in which they are incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks, using information provided to us by our vendors and analyzing the progress of our clinical trials or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period. Research and development activities are central to our business model. We expect our research and development expenses to increase substantially for the foreseeable future as we advance LB-102and any of our future product candidates into and through later stage clinical trials, pursue regulatory approval of our product 99

candidates, build our operational and commercial capabilities for supplying and marketing our products, if approved, and expand our pipeline of product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. Furthermore, product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. The actual probability of success for our product candidates may be affected by a variety of factors, including the safety and efficacy of our product candidates, conduct of clinical trials, investment in our clinical programs, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion of costs of our research and development projects or if, when, and to what extent we will generate revenue from the commercialization and sale of LB-102or any future product candidates, if approved by the FDA and other applicable regulatory authorities. Our future research and development costs may vary significantly based on factors such as:

| • |     | the timing and progress of our clinical development activities; |

| • |     | the number and scope of preclinical and clinical programs we decide to pursue; |

| • |     | the amount and timing of any milestone payment due under an existing, or any future, license or collaboration 
 agreement or asset acquisition;                                                                               |

| • |     | the number of patients that participate in our clinical trials, and per participant clinical trial costs; |

| • |     | the number and duration of clinical trials required for approval of our product candidates; |